| 1 |
34203690 | Bioactivation of Isoxazole-Containing Bromodomain and Extra-Terminal Domain (BET) Inhibitors. | 2021 Jun 15 |
1 |
| 2 |
29189147 | Disrupting Acetyl-lysine Interactions: Recent Advance in the Development of BET Inhibitors. | 2018 |
1 |
| 3 |
29561307 | Synergistic in-vitro effects of combining an antiglycolytic, 3-bromopyruvate, and a bromodomain-4 inhibitor on U937 myeloid leukemia cells. | 2018 Jun |
1 |
| 4 |
27707886 | Exploitation of Castration-Resistant Prostate Cancer Transcription Factor Dependencies by the Novel BET Inhibitor ABBV-075. | 2017 Jan |
1 |
| 5 |
28277835 | Selective targeting of epigenetic reader domains. | 2017 May |
1 |
| 6 |
25323695 | Chemical biology. A bump-and-hole approach to engineer controlled selectivity of BET bromodomain chemical probes. | 2014 Oct 31 |
1 |
| 7 |
23939492 | BET acetyl-lysine binding proteins control pathological cardiac hypertrophy. | 2013 Oct |
2 |
| 8 |
21964340 | Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia. | 2011 Oct 2 |
1 |
| 9 |
17848202 | Solution structure of the second bromodomain of Brd2 and its specific interaction with acetylated histone tails. | 2007 Sep 12 |
1 |